Obesity will affect over half of adults in 25 years, study predicts
A team of researchers found that in 2021, one billion men and 1.11 billion women over 25 years of age worldwide qualified as overweight or obese — twice as many as in 1990.
In 2021, more than half of the world's overweight and obese adults lived in eight countries: China (402 million), India (180 million), the U.S. (172 million), Brazil (88 million), Russia (71 million), Mexico (58 million), Indonesia (52 million), and Egypt (41 million), according to a press release.
This Disease Kills More People Than All Cancers And Accidents Combined
If the increase continues at this same pace, the study projects that more than half (57.4%) of men and 60.3% of women will be overweight or obese by 2050.
The three countries expected to have the highest rates of overweight or obesity by 2050 are China (627 million people), India (450 million) and the U.S. (214 million).
Read On The Fox News App
The study also found that by 2050, nearly one-quarter of obese adults will be 65 or older.
The researchers analyzed data from the Global Burden of Diseases, Injuries, and Risk Factors Study, spanning 204 countries and territories.
Ozempic's Health Benefits Keep Growing, But Are The Risks Worth It?
"The unprecedented global epidemic of overweight and obesity is a profound tragedy and a monumental societal failure," said lead author Professor Emmanuela Gakidou from the Institute for Health Metrics and Evaluation (IHME), University of Washington, in the release.
"Governments and the public health community can use our country-specific estimates on the stage, timing and speed of current and forecasted transitions in weight to identify priority populations experiencing the greatest burdens of obesity who require immediate intervention and treatment, and those that remain predominantly overweight and should be primarily targeted with prevention strategies."
Another finding was that "more recent generations are gaining weight faster than previous ones and obesity is occurring earlier."
This increases the risk of younger people developing obesity-related conditions like type 2 diabetes, high blood pressure, cardiovascular diseases and multiple cancers.
There were some limitations to the study, the researchers acknowledged.
"Predictions are constrained by the quantity and quality of past data as well as systemic biases from self-reported data, which are likely to remain despite attempts to correct for bias," they wrote.
They also noted that the definition of overweight and obesity is based on BMI (body mass index), "which does not account for variations in body structure across ethnic groups and subpopulations."
The study also did not take into account the effects of GLP-1 anti-obesity medications and other interventions.
Brett Osborn, a Florida neurosurgeon and longevity expert at Senolytix, called out obesity as the "single greatest modifiable threat to longevity, economic stability and national security."
"Yet, instead of confronting the problem head-on, our culture continues to coddle bad habits, normalize obesity and abandon personal responsibility," he said in a statement to Fox News Digital.
Weight Loss May Be Helped By Drinking This, Study Suggests
"This crisis is not about food deserts genetics or corporate greed — it's about choices. And we are making the wrong ones."
The obesity crisis can be linked to sedentary lifestyles, ultraprocessed foods and an "entitlement mentality that demands a pill for every problem," according to Osborn.
"The reality is simple: Obesity is caused by caloric surplus and a lack of movement," he said. "When you consistently eat more calories than you burn, you gain weight. Period."
If cases rise to the study's projections by 2050, Osborn warned that "obesity-related diseases will cripple healthcare systems worldwide."
Click Here To Sign Up For Our Health Newsletter
"The recent Lancet study projects over 1.3 billion global diabetes cases and more than two million obesity-driven cancers annually," he said. "Cardiovascular disease will double in prevalence across multiple regions, and the economic burden will exceed $4 trillion per year. This is unsustainable."
"Our healthcare system was never designed to support a world where over half the population has a preventable, self-inflicted disease."
The fight against obesity isn't about aesthetics, Osborn said — "nor is this a personal affront to overweight or categorically obese people. This is about survival."
"The world has two choices: Act aggressively now or pay an unfathomable price later," he went on.
"The time to fight obesity — relentlessly and unapologetically — is now."
For more Health articles, visit www.foxnews.com/health
The study was funded by the Bill & Melinda Gates Foundation. It was conducted by the GBD 2021 Adolescent and Adult BMI Collaborators. Fox News Digital reached out to the researchers for comment.Original article source: Obesity will affect over half of adults in 25 years, study predicts
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
27 minutes ago
- Business Wire
Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that the first participant has been enrolled in Marea's Phase 1 study evaluating MAR002 for the treatment of acromegaly. Acromegaly is a chronic, rare, systemic disease most often caused by a growth hormone (GH)-secreting pituitary adenoma, leading to the overproduction of insulin-like growth factor 1 (IGF-1) which mediates the characteristic somatic overgrowth and multisystem involvement observed in affected individuals. The primary objective of medical therapy for acromegaly is to normalize IGF-1 levels according to age and sex. 'Dosing our first participant in this Phase 1 study of MAR002 is a critical milestone for Marea Therapeutics and brings us closer to addressing the significant unmet needs of patients with acromegaly,' said Josh Lehrer, M.D., chief executive officer of Marea Therapeutics. 'We believe MAR002's unique properties, including an allosteric mechanism of action, could make it a differentiated and optimal medical therapy for acromegaly, increasing the effectiveness and reducing the burden associated with current therapies.' The MAR-201 study is a first-in-human (FIH), randomized, blinded, parallel-group, placebo-controlled single ascending dose (SAD) study in healthy men. Key objectives of the study include: Primary Objective: To evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002, assessed by treatment-emergent adverse events (TEAEs), vital signs, physical examinations, safety laboratories, and electrocardiograms (ECGs). Secondary Objective: To evaluate the pharmacokinetics (PK) of SC administration of MAR002 Exploratory Objectives: To evaluate the effect of SC administration of MAR002 on serum IGF-1 levels (pharmacodynamics [PD]/efficacy) and to assess the immunogenicity. About MAR002 MAR002 is a potent and selective half-life-extended, allosteric, human monoclonal growth hormone receptor antagonist (GHRA) antibody being developed for the treatment of acromegaly. The in vivo PK and PD properties of MAR002 are predictable and typical of a half-life extended human antibody, showing a long duration of action compatible with infrequent subcutaneous dose administration in humans. These characteristics support its potential to offer an effective and convenient treatment for patients with acromegaly. About Acromegaly Acromegaly is an orphan disease characterized by the excess secretion of growth hormone (GH) from a benign pituitary adenoma. Acromegaly affects approximately 30,000 patients in the U.S. If left untreated, acromegaly is highly morbid, leading to significant comorbidities such as GH-induced insulin resistance and diabetes, and serious cardiovascular pathology. The median lifespan of patients can be shortened by 10 years without effective therapy, and incomplete IGF-1 normalization is associated with increased mortality. Despite its severity, acromegaly is often under or misdiagnosed, with an average time from symptom onset to diagnosis of approximately eight years. The current treatment paradigm for acromegaly often involves surgery, performed in over 90% of patients, which achieves remission in about 50% of cases, though this can degrade over time. Medical therapy is required for approximately 65% (around 20,000 in the U.S.) of patients during their disease journey. Current medical treatments include somatostatin receptor ligands (SRLs) and growth hormone receptor antagonist (GHRA) pegvisomant. However, most patients do not achieve biochemical control with existing therapies. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company's lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for atherosclerotic cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit and follow us on LinkedIn and X.


Business Insider
9 hours ago
- Business Insider
How Wall Street Skipped a Beat on Hims & Hers Health Stock (HIMS)
Hims & Hers Health (HIMS) is one of the market's most hotly debated stocks. The telehealth platform is shaking up personalized healthcare, delivering affordable treatments for everything from hair loss to weight management. It has its die-hard fans and vocal critics—and after the stock slid following its latest Q2 report published last week on August 4th, the bears might seem to be winning the argument. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Yes, revenue fell short of Wall Street's sky-high expectations, and the booming obesity drug market faced some turbulence. But in my view, the market is missing the bigger picture. This was a stellar quarter—marked by explosive growth and strategic moves that scream long-term upside. And with the valuation still looking like a bargain, HIMS remains a cornerstone of my portfolio. I think now is a perfect time to buy the dip on HIMS stock, given the overshoot in bearish sentiment. Why Wall Street Freaked Out Wall Street can often be a drama queen, and HIMS felt the wrath post-earnings. The telehealth company reported revenue of $544.8 million, a solid 73% year-over-year jump, but it fell short of the $552 million analysts expected. The miss stung, especially after a stellar Q1 with 111% growth. It can be attributed mainly to regulatory headwinds in the compounding obesity drug market. The FDA called off the shortage allowance for GLP-1 knockoffs in February 2025, forcing HIMS to pivot from mass-producing these cheaper alternatives. Add to that a busted deal with Novo Nordisk (NVO), which sent shares spiraling back in June, and you've got a recipe for investor jitters. Legal risks are also looming, with Novo Nordisk filing various lawsuits against telehealth players for pushing 'personalized' compounded drugs. Beyond the revenue miss, gross margins took a hit, slipping from Q1's highs, and HIMS's third-quarter guidance of $580 million at the midpoint felt lukewarm compared to Wall Street's hopes. You can thus understand why investors got scared, troubled that HIMS's heavy reliance on GLP-1s might clip its wings. However, let's take a step back, as Wall Street's short-term tantrum is likely missing the bigger picture here. Growth That's Still Red-Hot Despite the noise, HIMS is charging forward like a freight train. Subscriber growth was quite impressive, with the company reaching 2.4 million users, up 31% from last year, demonstrating the platform's sticky appeal, which offers tailored solutions for weight loss, dermatology, and more. Notably, revenue grew 73% to $544.8 million, driven by booming demand for telehealth weight-loss services and personalized offerings. And the critical factor here is that the company is not just relying on obesity drugs. In fact, its dermatology segment is growing over 50% year-over-year, with 80% of that business now tied to proprietary, personalized SKUs that boosted retention by 20%. HIMS also completed some key moves this quarter including Zava, a U.K.-based telehealth player that should, in turn, set the stage for expansion into Germany, Ireland, and France. Looking ahead, the company is eyeing Canada in 2026, timed with the arrival of generic semaglutide, which could slash prices to $75-$100 from the current $200-$400 range. Plus, HIMS is diving into longevity and preventative care, with at-home lab testing and compounding facilities to personalize treatments like never before. So even though the market believes that GLP1-related pressures present a notable risk, I see that HIMS is building a healthcare ecosystem that's poised to keep revenue climbing. Is HIMS a Good Stock to Buy? There are 11 analysts offering price targets on HIMS stock via TipRanks, featuring a very mixed consensus. As I mentioned earlier, this is a highly polarizing stock. Evidently, the stock carries a Hold consensus rating based on three Buy, six Hold, and two Sell ratings over the past three months. HIMS' average stock price target of $51.33 implies about 1% downside over the next twelve months, which also reflects Wall Street's concerns about the telehealth innovator. A Valuation That's Too Good to Ignore HIMS's valuation is where things get juicy. The market's hung up on the GLP-1 drama, but that's just one piece of the puzzle. HIMS is trading at under 5x sales, which I believe is a dirt-cheap multiple for a company growing revenue at 73% and subscribers at 31%. Sure, the P/E ratio's sitting at 83x this year's expected EPS, which might raise eyebrows. However, profitability is set to surge from here. Analysts are projecting 41% EPS growth next year alone, meaning that P/E will shrink fast as profits catch up. Regulatory risks are still a big deal for HIMS. But make no mistake, as this company isn't just hanging on to compounded drugs. They're clearly building a fast-growing platform that covers weight loss, skincare, low testosterone, menopause care, and now longevity. The Zava acquisition and Canada expansion will only fuel that growth further. HIMS' Short-Term Noise Heralds Long-Term Opportunity While Wall Street zeroed in on HIMS's short-term hiccups, the company's long-term story remains intact and compelling. With explosive subscriber growth and expanding product lines, HIMS is quietly building a diversified, future-ready healthcare platform. The GLP-1 drama may have rattled the market, but I believe it's just noise in a much bigger narrative. For those with patience and vision, HIMS offers a rare blend of innovation, scalability, and upside that's too promising to ignore, especially after the post-earnings plunge.
Yahoo
12 hours ago
- Yahoo
Novo Nordisk Reduces Sales And Operating Profit Outlook For 2025
Novo Nordisk A/S (NYSE:NVO) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to 10–16% (from 16-24%) and revenue growth projections to 8-14% (from 13-21%) at constant currency rates in its 2025 full-year guidance. The projection shows lower demand for Wegovy® and Ozempic® in the United States and a few foreign markets, despite an 18% sales and 29% profit increase in H1 2025. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The downgrading is attributed to the decreased adoption of Wegovy, resulting from continued sales of compounded GLP-1s, even after the FDA's mass compounding grace period expired in May. The weekly prescriptions through NovoCare® Pharmacy are 11,000, with an additional 20,000 in retail cash channels. Novo Nordisk A/S (NYSE:NVO) is taking legal action and extending its telehealth and pharmaceutical collaborations. Growing competition is another factor putting pressure on Ozempic® sales in the US. Furthermore, adoption in global markets for obesity has been modest. Novo Nordisk A/S (NYSE:NVO) anticipates a DKK 3 billion net financial gain from currency hedging and DKK 35-45 billion in free cash flow. Full H1 financials will be available on August 6, 2025. It is among the Best Weight Loss Stocks. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data